Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)
Findings suggest semaglutide 2.4 mg and tirzepatide are used in descriptively similar populations and both resulted in clinically meaningful weight loss after 1 year of treatment.
Authors
- Mandy Buss
- Carmen D. Ng (ORCID: https://orcid.org/0000-0001-9453-7818)
- Victoria Divino (ORCID: https://orcid.org/0000-0001-5555-7912)
- Joshua C. Toliver (ORCID: https://orcid.org/0000-0002-9159-2587)
- Julia Wang (ORCID: https://orcid.org/0000-0003-0343-9820)
Institutions
- Novo Nordisk (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1007/s12325-025-03340-2
- Citations
- 9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 11.65
Funders
- Novo Nordisk